Ixekizumab
- Generic Name
- Ixekizumab
- Brand Names
- Taltz
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1143503-69-8
- Unique Ingredient Identifier
- BTY153760O
- Background
Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflammatory conditions. In particular, IL-17A h...
- Indication
Ixekizumab is indicated for the treatment of patients aged six years or older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. It is also indicated in adult patients with active psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis with objective signs of inflammation.
- Associated Conditions
- Moderate to Severe Plaque Psoriasis, Active Ankylosing spondylitis, Active Non-radiographic Axial Spondyloarthritis, Active Psoriatic arthritis
- Associated Therapies
- -
A Study of Two Formulations of Ixekizumab in Healthy Participants
- First Posted Date
- 2020-02-06
- Last Posted Date
- 2022-04-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 245
- Registration Number
- NCT04259346
- Locations
- 🇺🇸
Covance Clinical Research Inc, Madison, Wisconsin, United States
🇺🇸Covance Dallas, Dallas, Texas, United States
🇺🇸Miami Research Associates, Miami, Florida, United States
A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2019-05-08
- Last Posted Date
- 2021-08-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 12
- Registration Number
- NCT03942042
- Locations
- 🇯🇵
Jikei University School of Medicine, Minato-Ku, Tokyo, Japan
🇯🇵Tokyo Medical University Hospital, Shinjuku-ku, Tokyo, Japan
🇯🇵Teikyo University Hospital, Itabashi-ku, Tokyo, Japan
A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2018-06-29
- Last Posted Date
- 2020-07-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1027
- Registration Number
- NCT03573323
- Locations
- 🇺🇸
Johnson Dermatology, Fort Smith, Arkansas, United States
🇺🇸Arlington Research Center, Inc, Arlington, Texas, United States
🇺🇸Dermatology Clinical Trials, Newport Beach, California, United States
Ixekizumab in the Treatment of Pityriasis Rubra Pilaris (PRP)
- First Posted Date
- 2018-04-03
- Last Posted Date
- 2020-07-01
- Lead Sponsor
- Oregon Health and Science University
- Target Recruit Count
- 12
- Registration Number
- NCT03485976
- Locations
- 🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
A Study of Ixekizumab (LY2439821) in Chinese Participants With Moderate-to-Severe Plaque Psoriasis
- First Posted Date
- 2017-12-06
- Last Posted Date
- 2021-06-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 438
- Registration Number
- NCT03364309
- Locations
- 🇨🇳
The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
🇨🇳The First Affiliated Hospital with Nanjing Medical University, Nanjing, Nanjing, China
🇨🇳Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China
Molecular Signatures in Inflammatory Skin Disease
- First Posted Date
- 2017-11-30
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Prof. Dr. Stephan Weidinger
- Target Recruit Count
- 300
- Registration Number
- NCT03358693
- Locations
- 🇩🇪
Department of Dermatology, University Hospital Schleswig Holstein, Campus Kiel, Kiel, Germany
A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2020-11-03
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 566
- Registration Number
- NCT03151551
- Locations
- 🇮🇳
Sir Ganga Ram Hospital, New Delhi, Delhi, India
🇧🇪Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven, Belgium
🇮🇳Krishna Institute of Medical Sciences Ltd., Secunderabad, Telengana, India
A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis
- First Posted Date
- 2017-04-26
- Last Posted Date
- 2022-06-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 773
- Registration Number
- NCT03129100
- Locations
- 🇺🇸
Physician Research Collaboration, LLC, Lincoln, Nebraska, United States
🇺🇸Arthritis Rheumatic Disease Specialties, Aventura, Florida, United States
🇨🇦University of Alberta Hospital, Edmonton, Alberta, Canada
Ixekizumab in the Treatment of Bullous Pemphigoid
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2020-05-21
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 4
- Registration Number
- NCT03099538
- Locations
- 🇺🇸
Mayo Clinic, Scottsdale, Arizona, United States
A Study of Ixekizumab in Chinese Participants With Psoriasis Vulgaris
- First Posted Date
- 2017-03-08
- Last Posted Date
- 2020-07-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 32
- Registration Number
- NCT03073213
- Locations
- 🇨🇳
Xiangya Hospital, Central South University, Changsha, Hunan, China
🇨🇳Second Affiliate Hospital of Zhejiang Medical University, Hangzhou, Zhejiang, China
🇨🇳Ruijin Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.